Today’s pharma deals map the full innovation cycle, spanning oral biologics discovery, vaccine market access, and gene-therapy regulatory approval.
Gilead raised the bar in the long-acting HIV prevention race with once-yearly lenacapavir and expanded global supply planning.
Pharma faces a pipeline paradox today as companies chase AI-powered R&D while trial failures, IP battles, and quality gaps widen.
Alkem’s NeuCeno brings cenobamate to Indian patients, offering a once-daily anti-seizure treatment option for adults with partial-onset seizures.
FDA Today brings fresh developments across drug access, approvals and new pathways, spanning oncology, respiratory care and emerging psychedelic therapies.
Pharma’s rough patch deepens as fines, clinical failures and market fallout put safety, efficacy and investor confidence under pressure.
India’s biopharma sector is gaining regulatory strength as Biopharma SHAKTI and IPC’s quality push support biologics and biosimilars growth.
Trial results today are reshaping pharma fortunes, with clinical successes boosting confidence while failures trigger sharp market reactions.
Pharma Today tracks how capital, investment and biosimilars shape new moves across India’s drug industry, with Sun Pharma, ChrysCapital and Lupin advancing distinct growth priorities.
Tylenol exposure in pregnancy draws fresh scrutiny as the latest evidence links prenatal exposure to reproductive changes in daughters.
.jpg)
, CDSCO.jpg)